AR125494A1 - Composición farmacéutica que comprende un agonista de gpr40 y un inhibidor de sglt-2 - Google Patents
Composición farmacéutica que comprende un agonista de gpr40 y un inhibidor de sglt-2Info
- Publication number
- AR125494A1 AR125494A1 ARP220101132A ARP220101132A AR125494A1 AR 125494 A1 AR125494 A1 AR 125494A1 AR P220101132 A ARP220101132 A AR P220101132A AR P220101132 A ARP220101132 A AR P220101132A AR 125494 A1 AR125494 A1 AR 125494A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- pharmaceutical composition
- inhibitor
- racemate
- diastereomer
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- DGENZVKCTGIDRZ-UHFFFAOYSA-N 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=CC(OC=2C=CC=CC=2)=C1 DGENZVKCTGIDRZ-UHFFFAOYSA-N 0.000 title abstract 4
- 229940125827 GPR40 agonist Drugs 0.000 title abstract 4
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 abstract 2
- 201000008980 hyperinsulinism Diseases 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 108091006269 SLC5A2 Proteins 0.000 abstract 1
- 102000058081 Sodium-Glucose Transporter 2 Human genes 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composición farmacéutica que incluye un agonista de GPR40 y un inhibidor de SGLT-2, un método de preparación de la misma, y un método de tratamiento de la diabetes mellitus de tipo 2 y similares utilizando la misma. Reivindicación 1: Una composición farmacéutica para el tratamiento de cualquier enfermedad caracterizada porque se selecciona del grupo que consiste en la diabetes mellitus de tipo 2, la hiperinsulinemia, el trastorno de tolerancia a la glucosa y el trastorno de resistencia a la insulina, la composición farmacéutica que comprende un compuesto representado por la fórmula (1), un racemato del compuesto, un enantiómero del compuesto, un diastereómero del compuesto o una sal farmacéuticamente aceptable del compuesto, el racemato, el enantiómero o el diastereómero y un inhibidor de SGLT2. Reivindicación 10: Un método de preparación de una composición farmacéutica para la prevención, el alivio o el tratamiento de cualquier enfermedad seleccionada del grupo que consiste en diabetes mellitus tipo 2, hiperinsulinemia, trastorno de tolerancia alterada a la glucosa y trastorno de resistencia a la insulina, y caracterizada porque el método comprende la formulación de un agonista de GPR40 y un inhibidor de SGLT2 junto con un excipiente farmacéuticamente aceptable o por separado, un excipiente, portador o diluyente farmacéuticamente aceptable, y el agonista de la GPR40 es un compuesto representado por la fórmula (1), un racemato del compuesto, un enantiómero del compuesto, un diastereómero del compuesto o una sal farmacéuticamente aceptable del compuesto, el racemato, el enantiómero o el diastereómero.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210055992 | 2021-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125494A1 true AR125494A1 (es) | 2023-07-19 |
Family
ID=83848392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101132A AR125494A1 (es) | 2021-04-29 | 2022-04-29 | Composición farmacéutica que comprende un agonista de gpr40 y un inhibidor de sglt-2 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4329756A1 (es) |
| JP (1) | JP2024515137A (es) |
| KR (1) | KR20240004285A (es) |
| CN (1) | CN117241798A (es) |
| AR (1) | AR125494A1 (es) |
| AU (1) | AU2022266499A1 (es) |
| BR (1) | BR112023022114A2 (es) |
| CA (1) | CA3217858A1 (es) |
| IL (1) | IL307623A (es) |
| MX (1) | MX2023012835A (es) |
| TW (1) | TW202308620A (es) |
| UY (1) | UY39744A (es) |
| WO (1) | WO2022231357A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102007633B1 (ko) * | 2016-12-15 | 2019-08-06 | 일동제약(주) | 신규 페닐 프로피온 산 유도체 및 이의 용도 |
| KR20240084229A (ko) * | 2022-12-06 | 2024-06-13 | 유노비아 주식회사 | 안정성이 향상된 gpr40 효현제를 유효성분으로 포함하는 약제학적 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007033002A1 (en) * | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| US10195178B2 (en) * | 2016-04-11 | 2019-02-05 | Janssen Pharmaceutica Nv | GPR40 agonists in anti-diabetic drug combinations |
| CN108430467B (zh) * | 2016-05-20 | 2021-06-22 | 晟德大药厂股份有限公司 | (r)-(+)-维拉帕米用于治疗高血糖的用途及其药学组合物 |
| KR101934328B1 (ko) * | 2016-08-12 | 2019-01-02 | 주식회사 노브메타파마 | 아모디아퀸 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물 |
| KR102007633B1 (ko) * | 2016-12-15 | 2019-08-06 | 일동제약(주) | 신규 페닐 프로피온 산 유도체 및 이의 용도 |
-
2022
- 2022-04-28 CN CN202280031057.0A patent/CN117241798A/zh active Pending
- 2022-04-28 CA CA3217858A patent/CA3217858A1/en active Pending
- 2022-04-28 KR KR1020237034149A patent/KR20240004285A/ko unknown
- 2022-04-28 UY UY0001039744A patent/UY39744A/es unknown
- 2022-04-28 IL IL307623A patent/IL307623A/en unknown
- 2022-04-28 TW TW111116273A patent/TW202308620A/zh unknown
- 2022-04-28 BR BR112023022114A patent/BR112023022114A2/pt unknown
- 2022-04-28 JP JP2023565557A patent/JP2024515137A/ja active Pending
- 2022-04-28 AU AU2022266499A patent/AU2022266499A1/en active Pending
- 2022-04-28 MX MX2023012835A patent/MX2023012835A/es unknown
- 2022-04-28 EP EP22796189.3A patent/EP4329756A1/en active Pending
- 2022-04-28 WO PCT/KR2022/006120 patent/WO2022231357A1/en active Application Filing
- 2022-04-29 AR ARP220101132A patent/AR125494A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240004285A (ko) | 2024-01-11 |
| MX2023012835A (es) | 2023-11-08 |
| WO2022231357A1 (en) | 2022-11-03 |
| IL307623A (en) | 2023-12-01 |
| JP2024515137A (ja) | 2024-04-04 |
| UY39744A (es) | 2022-11-30 |
| AU2022266499A1 (en) | 2023-11-09 |
| CA3217858A1 (en) | 2022-11-03 |
| CN117241798A (zh) | 2023-12-15 |
| TW202308620A (zh) | 2023-03-01 |
| BR112023022114A2 (pt) | 2024-01-30 |
| EP4329756A1 (en) | 2024-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR125494A1 (es) | Composición farmacéutica que comprende un agonista de gpr40 y un inhibidor de sglt-2 | |
| FI3989972T3 (fi) | Glukakonin kaltainen peptidi 1 reseptorin agonistit | |
| CO5700796A2 (es) | Composiciones que contienen piperacilina y tazobactam utiles para inyecciones | |
| BR112022018646A2 (pt) | Composto agonista do receptor glp-1, composição farmacêutica compreendendo o mesmo, métodos para preparar o composto e uso do dito composto para prevenir ou tratar uma doença metabólica ou uma doença neurodegenerativa | |
| CO6260081A2 (es) | Un medicamento para tratar o prevenir trastornos metabolicos que contiene un agonista nachr (alfa)7 selectivo | |
| CL2022003360A1 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578) | |
| AR062536A1 (es) | Acilanilidas sustituidas y composicion farmaceutica | |
| UY31295A1 (es) | Composicion farmacéutica que comprende un inhibidor de sglt2 | |
| BRPI0416283A (pt) | compostos, processo para a fabricação de compostos, composição farmacêutica, método para o tratamento e/ou prevenção de doenças que são moduladas por agonistas de ppar(delta) e/ou ppar(alfa) e uso destes compostos | |
| AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
| DK1845095T3 (da) | 1-thio-D-glucitolderivater | |
| AR069541A1 (es) | Trans- clomifeno para el sindrome metabolico | |
| AR083679A1 (es) | Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos | |
| AR074107A1 (es) | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina | |
| AR112284A1 (es) | Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico | |
| BR112022008786A2 (pt) | Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose | |
| MX2022013588A (es) | Combinación de fármacos para tratar la diabetes mellitus y sus complicaciones y composición farmacéutica de la combinación de fármacos. | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| AR060977A1 (es) | Aminotiazoles y sus usos | |
| BRPI0407303A (pt) | Composição farmacêutica | |
| CL2020003143A1 (es) | Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
| FI3737470T3 (fi) | 3-fenyyli-4-heksyylihappojohdannaisia GPR40-agonisteina | |
| AR062779A1 (es) | Tratamiento de la esclerosis multiple (em) | |
| CO2022014853A2 (es) | Compuesto novedoso [2-(dimetilamino)-2-fenilbutil]-3,4,5-trimetoxibenzoato 4-metil-2h-cromen-2-on-7-il sulfato y uso del mismo | |
| AR045423A1 (es) | Combinaciones de analiticos y antidepresivos |